ライフサイエンスコーパス: SARS

1 SARS-CoV-2 has a zoonotic origin and was transmitted to

2 SARS-CoV-2 has been detected in the CSF of some patients

3 SARS-CoV-2 is a new member of the betacoronavirus genus

4 SARS-CoV-2 is responsible for the development of coronav

5 SARS-CoV-2 MA caused more severe disease in aged mice, a

6 SARS-CoV-2 may modulate macrophage-mediated inflammation

7 SARS-CoV-2 spike glycoprotein (S)-reactive antibodies we

8 SARS-CoV-2 viral loads, especially plasma viremia, are a

9 SARS-CoV-2 was detected by RT-qPCR and viral culture; th

10 SARS-CoV-2-specific memory CD8(+) T cells exhibited func

11 SARS-CoV-2-specific T cell responses were driven by TCR

12 SARS-CoV-2-uninfected donor sera exhibited specific neut

13 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and 9,385 reported deaths.

14 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and an existing pandemic of metabolic diseas

15 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the risk of subsequent reinfection remai

16 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being expedited through preclinical and

17 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) based on reverse transcriptase polymerase ch

18 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in China and rapidly spread worldwid

19 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019(1,2) and is respons

20 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has elicited an equally rapid response aimin

21 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the environment are summarized and discus

22 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into Scotland using a combined phylogenetic

23 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause of an ongoing pandemic that has

24 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiological agent of the currently un

25 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disea

26 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has devastated global public health

27 The SARS coronavirus 2 (SARS-CoV-2) pandemic is a global challenge, which the sc

28 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic.

29 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients indicate that a cytokine

30 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevalence and the case-fatality rate during

31 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA in respiratory samples is the standard m

32 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, used in a combined cocktail (

33 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that results in excessive inflammation and r

34 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission networks became established in

35 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causes a pathogenic condition that has been

36 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a

37 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a member of the Coronaviridae family of

38 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease

39 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2), while striving to find a suitable vaccine t

40 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

41 re acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

42 re acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) infection increase the risk for acute nonisc

43 to both wild-type (D614) and D614G mutant(2) SARS-CoV-2 as well as CD8(+) T cell responses, and prote

44 human betacoronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

45 m for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains

46 spike D614G substitution in the USA-WA1/2020 SARS-CoV-2 strain, and found that it enhances viral repl

47 ere, with a focus on Israel, we sequence 212 SARS-CoV-2 sequences and use them to perform a comprehen

48 two subsequent analyses of 6,228 and 38,248 SARS-CoV-2 genomes which became available later.

49 unctional elements within the massive, ~30kb SARS-CoV-2 RNA genome.

50 Sequencing of 1,314 SARS-CoV-2 viral genomes from available patient samples

51 We analyzed 453 SARS-CoV-2 genomes collected between 20 February and 15

52 Here, we generate 649 SARS-CoV-2 genome sequences from infected patients in Ne

53 globally distributed haplotypes from 15,789 SARS-CoV-2 genomes and model their success based on thei

54 t continued organ transplantation, even in a SARS-CoV-2 hyperendemic area.

55 ut serological assays (HTSAs) and the Abbott SARS-CoV-2 IgG assay quantify levels of antibodies that

56 ify convergence of antibody sequences across SARS-CoV-2-infected patients, highlighting stereotyped n

57 Acute SARS-CoV-2 infection leaves protracted beneficial (ie, a

58 In summary, the mouse-adapted SARS-CoV-2 MA model demonstrates age-related disease pat

59 Additionally, SARS-CoV-2-specific memory lymphocytes exhibited charact

60 ibody responses in children and adults after SARS-CoV-2 infection.

61 ent and to treat the acute lung injury after SARS-CoV-2 infection, especially for those with the ACE

62 not sufficient to prevent transmission after SARS-CoV-2 introduction into this facility.

63 bited specific neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes.

64 erapeutic and/or prophylactic agents against SARS-CoV-2.

65 S adult population formed antibodies against SARS-CoV-2, and fewer than 10% of those with antibodies

66 ifying antiviral compounds effective against SARS-CoV-2.

67 n of commercial antibodies generated against SARS-CoV spike protein and nucleoprotein, double strande

68 e prophylactic effectiveness of IFNs against SARS-CoV-2.

69 or immunoglobulin detection produced against SARS-CoV-2.

70 titres are sufficient for protection against SARS-CoV-2 in rhesus macaques, and that cellular immune

71 D8(+) T cell responses, and protects against SARS-CoV-2 infection in the lungs and noses of mice with

72 T cell reactivity against SARS-CoV-2 was observed in unexposed people; however, th

73 Neutralising antibody responses against SARS-CoV-2 were detected in 32 (91%) of 35 participants

74 y-based countermeasures and vaccines against SARS-CoV-2.

75 he origin and emergence of its causal agent, SARS-CoV-2, in the human population remains mysterious,

76 ross 145 HLA-A, -B, and -C genotypes for all SARS-CoV-2 peptides.

77 NAs merit further development as alternative SARS-CoV-2 vaccines.

78 neutralizing activity against SARS-CoV-2 and SARS-CoV-2 S pseudotypes.

79 tion between the detected level of human and SARS-CoV-2 nucleic acids.

80 nowledge regarding genetic polymorphisms and SARS-CoV-2 and COVID-19.

81 ute respiratory syndrome coronavirus 2 (anti-SARS-CoV-2) antibodies provide one method for estimating

82 t individuals who were seronegative for anti-SARS-CoV-2 antibodies targeting spike (S) and nucleoprot

83 research needs pertaining to the use of anti-SARS-CoV-2 antibody tests for diagnosis, public health s

84 and subsequently tested with samples of anti-SARS-CoV-2 monoclonal antibody CR3022 (0.1 mug/ml, 1.0 m

85 We then measured the abundance of anti-SARS-CoV-2 S1 IgG in 16 convalescent COVID-19 patients.

86 We found that the Ortho anti-SARS-CoV-2 total Ig and IgG high-throughput serological

87 As SARS-CoV-2 infections and death counts continue to rise,

88 odies was able to potently inhibit authentic SARS-CoV-2 infection at a concentration as low as 0.007

89 ing model to analyze the correlation between SARS-CoV-2 test results and 20 routine laboratory tests

90 ad nanobody candidate, NIH-CoVnb-112, blocks SARS-CoV-2 spike pseudotyped lentivirus infection of HEK

91 ctivator of transcription signaling, boosted SARS-CoV-2 replication in the IFN-competent Calu-3 cells

92 Both SARS-CoV and MERS-CoV have caused serious outbreaks and

93 macromolecule is involved in ARDS caused by SARS-CoV-2.

94 f neutralizing antibodies (nAbs) elicited by SARS-CoV-2 infection is crucial for understanding immune

95 strains of mice are not readily infected by SARS-CoV-2 because of species-specific differences in th

96 ntify host factors required for infection by SARS-CoV-2 and seasonal coronaviruses, we designed a foc

97 t nucleocapsid antigen specifically captures SARS-CoV-2 antibodies in patient specimens.

98 In Vero E6 and in Calu3 cells, SARS-CoV-2 is substantially attenuated in the context of

99 polymerase (RdRp) are the best characterized SARS-CoV-2 targets and show the highest degree of conser

100 ow present at low frequencies in circulating SARS-CoV-2 populations.

101 onstrate that even under extreme conditions, SARS-CoV-2 virus is unable to replicate in these mosquit

102 Among 51 patients with confirmed SARS-CoV-2 infections, 23 (45.1%), 24 (47.1%), and 22 (4

103 In contrast, SARS-CoV-2 can be detected in the stool of some patients

104 Like other coronaviruses, SARS-CoV-2 is thought to have been transmitted to humans

105 well as severe illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

106 dies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on the envelo

107 evere illness and death (MERS-CoV, SARS-CoV, SARS-CoV-2).

108 ulture; the limit of detection for culturing SARS-CoV-2 from surfaces was determined.

109 In contrast to DENV, SARS and MERS CoVs predominantly infect respiratory epit

110 inical isolate, the infectious-clone-derived SARS-CoV-2 (icSARS-CoV-2) exhibited similar plaque morph

111 portable and real-time POC device to detect SARS-CoV-2 from VTM samples using an additively manufact

112 We were able to detect SARS-CoV-2-specific T cells in 10 of 10 COVID-19 patient

113 c people were less likely to have detectable SARS-CoV-2 in NTS collected at enrollment (8/13 [62%] vs

114 lateral flow immunoassay test that detected SARS-CoV-2 immunoglobulin G (IgG) and immunoglobulin M (

115 rovide a complementary method of determining SARS-CoV-2 infection status, based on a fully independen

116 Recovered individuals developed SARS-CoV-2-specific immunoglobulin (IgG) antibodies, neu

117 tic introduction of at least seven different SARS-CoV-2 lineages into California, including epidemic

118 sessed risk and incidence rate of documented SARS-CoV-2 reinfection in a cohort of laboratory-confirm

119 N-gamma protected mice from mortality during SARS-CoV-2 infection, sepsis, hemophagocytic lymphohisti

120 E2 is the receptor for the recently emerging SARS-CoV-2.

121 wed robust induction of chemokines following SARS-CoV-2 infection, similar to what is seen in patient

122 acturers have developed molecular assays for SARS-CoV-2 under the Food and Drug Administration (FDA)

123 rebrospinal fluid analyses were negative for SARS-CoV-2 in all patients tested (n = 39).

124 ic and symptomatic HCWs testing positive for SARS-CoV-2 rapidly declined to near-zero between 25th Ap

125 9 of the 640 throat swabs were positive for SARS-CoV-2 RNA by quantitative PCR, suggesting community

126 lised with pneumonia and tested positive for SARS-CoV-2.

127 ocumented symptoms with testing positive for SARS-CoV-2.

128 necessary for postpandemic preparedness for SARS-CoV-2.

129 Our recommendation for SARS-CoV-2 diagnostic testing is to select an assay with

130 liva offered sensitivity and specificity for SARS-CoV-2 detection comparable to that of the current s

131 We report a reverse genetic system for SARS-CoV-2.

132 Among 3,302 persons tested for SARS-CoV-2 by BinaxNOW TM and RT-PCR in a community sett

133 Study volunteers were tested for SARS-CoV-2 by means of quantitative polymerase-chain-rea

134 , 433 (64.8%) had previously been tested for SARS-CoV-2 RNA, and 50.0% had a positive RT-PCR result.

135 protein-reactive T cell lines generated from SARS-CoV-2-naive healthy donors responded similarly to t

136 uld potentially be developed to protect from SARS-CoV-2 and some other SARS-like viruses that might s

137 non-structural and accessory) proteins from SARS-CoV-2 using predictive algorithms to identify poten

138 emergence, plus 64 pandemic-era samples from SARS-CoV-2 PCR-negative patients with respiratory sympto

139 RS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-2 infections are generally restricted by human

140 Live virus challenge of animals given SARS or MERS vaccines resulted in vaccine hypersensitivi

141 pants with acute smell and/or taste loss had SARS-CoV-2 antibodies; of these, 39.8% (n = 175) had nei

142 Understanding how SARS-CoV-2 enters human cells is a high priority for dec

143 However, SARS-CoV-2 sera generally lacked cross-neutralization to

144 sons learned from cancer research may impact SARS-CoV-2 research and vice versa.

145 Importantly, SARS-CoV-2-specific T cells were detectable in antibody-

146 tive PUIs (n = 30) and viral coinfections in SARS-CoV-2 RT-PCR-positive PUIs (n = 45).

147 NVs may become an important consideration in SARS-CoV-2 classification and surveillance.

148 ecific CD8(+) T cells and were detectable in SARS-CoV-2 convalescent individuals who were seronegativ

149 ted benefits of lung function improvement in SARS-CoV infections, it has been hypothesized that the b

150 equencies of alternative viral infections in SARS-CoV-2 RT-PCR-negative PUIs (n = 30) and viral coinf

151 with renin-angiotensin system inhibitors in SARS-CoV-2 may outweigh the risks and at the very least

152 table using a flow cytometry-based method in SARS-CoV-2-uninfected individuals and were particularly

153 90% of the neutralizing activity present in SARS-CoV-2 immune sera.

154 he absence of the polybasic cleavage site in SARS-CoV-2 did not affect virus replication in Vero or V

155 centers in March through May 2020, including SARS-CoV-2 testing, well-child visits, HbA(1c) testing,

156 and fecal spread of enteric CoVs, including SARS-CoV-2.

157 like other closely related viruses including SARS-CoV and Middle East respiratory syndrome coronaviru

158 onses of human pathogenic viruses, including SARS-CoV2.

159 apacity and fate of pre-existing and induced SARS-CoV-2-specific CD8(+) T cell responses during the n

160 ex vivo analysis of pre-existing and induced SARS-CoV-2-specific CD8(+) T cells, applying peptide-loa

161 plicated in human betacoronavirus infection (SARS-CoV-2, SARS-CoV, MERS-CoV, seasonal coronaviruses).

162 ce stability was assessed using infectivity, SARS-CoV-2 survived on stainless steel, plastic, and nit

163 sults reveal possible mechanisms influencing SARS-CoV-2 infectivity and COVID-19 clinical outcomes.

164 omycin were confirmed to effectively inhibit SARS-CoV-2 replication in vitro with EC50 values of 0.00

165 potential therapies and vaccines to inhibit SARS-CoV-2 infection and ameliorate disease is the lack

166 brain organoids as a platform to investigate SARS-CoV-2 infection susceptibility of brain cells, mech

167 We investigated SARS-CoV-2 potential tropism by surveying expression of

168 vivo RNA-RNA interactome of the full-length SARS-CoV-2 genome and subgenomic mRNAs.

169 re utilized to compare Veritor with the Lyra SARS-CoV-2 PCR assay (Lyra).

170 The coronavirus family member, SARS-CoV-2 has been identified as the causal agent for t

171 evidence that complement function modulates SARS-CoV-2 infection outcome, the data point to putative

172 We find that most SARS-CoV-2 infections sampled during this time derive fr

173 hether they develop and sustain multifaceted SARS-CoV-2-specific immunological memory.

174 The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on

175 Notably, SARS-CoV-2 S variants that resist commonly elicited neut

176 019 (COVID-19), which is caused by the novel SARS-CoV-2, continues to spread rapidly around the world

177 It should increase the availability of SARS-CoV-2 testing as well as expand the settings in whi

178 atic function was mediated by the binding of SARS-CoV-2 spike RBD domain.

179 Knowing the concentration of SARS-CoV-2 S1-specific IgG is crucial in selecting appro

180 All patients had laboratory confirmation of SARS-CoV-2 infection.

181 susceptibility to and the natural course of SARS-CoV-2 infection.

182 cell responses during the natural course of SARS-CoV-2 infection.

183 cm(-2), respectively, toward detection of SARS-CoV-2 in biological media, while blind clinical eva

184 COVID-19 that may facilitate development of SARS-CoV-2 therapeutics and vaccines.

185 The emergence of SARS-CoV-2 has driven a global research effort to identi

186 The emergence of SARS-CoV-2 has resulted in >90,000 infections and >3,000

187 , and be a key component in the evolution of SARS-CoV-2 with this structural loop affecting virus sta

188 nt positions throughout the entire genome of SARS-CoV-2.

189 ospitals from becoming independent 'hubs' of SARS-CoV-2 transmission, and illustrate how, with approp

190 y and on projections of the global impact of SARS-CoV-2 on the human population, and assess its plaus

191 We investigated the incidence of SARS-CoV-2 infection confirmed by polymerase chain react

192 of age and females had a lower incidence of SARS-CoV-2 infection than adolescents or adults and male

193 D-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers after sympt

194 o show that template-dependent inhibition of SARS-CoV-2 RdRp by RDV is biologically relevant.

195 We also describe potent inhibition of SARS-CoV-2 strain 2019-nCoV/USA-WA1/2020 by Apilimod.

196 Thus, the K18-hACE2 model of SARS-CoV-2 infection shares many features of severe COVI

197 y of remdesivir in a rhesus macaque model of SARS-CoV-2 infection(9).

198 from the United States to inform a model of SARS-CoV-2 transmission.

199 ), S1+S2, nucleocapsid, and ORF6 to ORF10 of SARS-CoV-2, to the HCoV-OC43 and HCoV-HKU1 betacoronavir

200 ilding on knowledge of previous outbreaks of SARS-CoV-1 and Middle East respiratory syndrome (MERS),

201 %, 99%] specificity in predicting outcome of SARS-CoV-2 pneumonia.

202 ortant for understanding the pathogenesis of SARS-CoV-2, vaccine development, and therapeutic testing

203 The excretion pathomechanisms of SARS-CoV-2 are actually unknown.

204 n strategies must target both the potency of SARS-CoV-2 and its evasiveness.

205 We document the presence of SARS-CoV-2 RNA associated with platelets of COVID-19 pat

206 Antibody to the nucleocapsid protein of SARS-CoV-2 is more sensitive than spike protein antibody

207 s study characterizes the trends in rates of SARS-CoV-2 positive test results among individuals in th

208 The estimated odds ratio of SARS-CoV-2 prevalence between the cancer cohort and cont

209 coated with receptor binding domain (RBD) of SARS-CoV-2 spike protein, and subsequently tested with s

210 Low copy numbers (>=500 copies/reaction) of SARS-CoV-2 RNA were consistently detected by the multipl

211 p of ISMs to phylogenetic reconstructions of SARS-CoV-2 evolution, and therefore, ISMs can play an im

212 The relationship of SARS-CoV-2 pulmonary infection and severity of disease i

213 As a result of SARS-CoV-2 binding, ACE2 downregulation enhances the ang

214 lity score that predicts an elevated risk of SARS-CoV-2 infection for multiple species including hors

215 possible postpandemic circulating season of SARS-CoV-2 and add to the knowledge pool necessary for p

216 udy aimed to determine the seroprevalence of SARS-CoV-2 antibodies in a community-based population wi

217 The international spread of SARS-CoV-2 is associated with the ease of global travel,

218 rings) that could help control the spread of SARS-CoV-2, particularly in hard-hit regions.

219 Despite the ability to dampen the spread of SARS-CoV-2, the causative agent of the diseases, through

220 tation (D839Y/N/E) from a European strain of SARS-CoV-2.

221 The spike protein on the surface of SARS-CoV-2 is a major antigen and its engagement with hu

222 onaviruses 229E and OC43, as well as that of SARS-CoV-2.

223 Geometric mean titres of SARS-CoV-2 serum-neutralizing antibodies on day 43 were

224 vailable data on the risk of transmission of SARS-CoV-2 through organ transplantation.

225 ole in the pathogenicity and transmission of SARS-CoV-2.

226 ve PCR, suggesting community transmission of SARS-CoV2 in Wuhan in early January 2020.

227 Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testi

228 e-type glycan clusters, which were absent on SARS and HKU1 CoVs.

229 Research on SARS-CoV-2, as well as the closely related SARS-CoV-1 an

230 ed to protect from SARS-CoV-2 and some other SARS-like viruses that might spillover into humans in th

231 ses (CoVs) identified in bats and pangolins, SARS-CoV-2 harbors a polybasic furin cleavage site in it

232 e obtained at least 14 days after a positive SARS-CoV-2 PCR.

233 VID-19 were defined as those with a positive SARS-CoV-2 test.

234 .9% NaCl prevents cellular infection with pp-SARS-CoV-2 spike.

235 ective antiviral that can be used to prevent SARS-CoV-2 infection.

236 ing and contact tracing could have prevented SARS-CoV-2 outbreaks from becoming established in these

237 noids from hiPSCs and showed that productive SARS-CoV-2 infection of these organoids is associated wi

238 argeting 332 members of a recently published SARS-CoV-2 protein interactome.

239 Rapid SARS-CoV-2 countermeasure development is contingent on t

240 n SARS-CoV-2, as well as the closely related SARS-CoV-1 and MERS coronaviruses, is restricted to BSL-

241 tourists and a family of 5 French residents; SARS-CoV-2 was detected in 5 individuals in France, 6 in

242 hage libraries that specifically bind the S1 SARS-CoV-2 spike protein, and block the interaction with

243 our findings provide evidence for selective SARS-CoV-2 neurotropism and support the use of hiPSC-der

244 The haplotypes of the sequenced SARS-CoV-2 viruses were diverse and changed over time.

245 on-gamma-based assays with peptides spanning SARS-CoV-2 except ORF1.

246 ant to mutation compared to species-specific SARS-CoV-2 RT-PCR assays.

247 ontrol-of severe acute respiratory syndrome (SARS) in 2003(5).

248 patient samples enabled us to estimate that SARS-CoV-2 was introduced to Scotland on at least 283 oc

249 Modeling indicates that SARS-CoV-2 control requires the synergistic efforts of c

250 Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV

251 Here we show that SARS-CoV-2 causes a respiratory disease in rhesus macaqu

252 We show that SARS-CoV-2 Spike-pseudotyped virus and genuine SARS-CoV-

253 The SARS coronavirus 2 (SARS-CoV-2) pandemic is a global cha

254 s collected within a 2-day period around the SARS-CoV-2 test date.

255 The COVID-19 pandemic caused by the SARS-CoV-2 has recently emerged as a serious jolt to hum

256 e 2019 (COVID-19), the illness caused by the SARS-CoV-2 virus, is rapidly spreading throughout the wo

257 e present a self-amplifying RNA encoding the SARS-CoV-2 spike protein encapsulated within a lipid nan

258 CoV (MERS-CoV), bat CoV HKU5 expressing the SARS-CoV-1 spike, and vesicular stomatitis virus (VSV) e

259 icular stomatitis virus (VSV) expressing the SARS-CoV-2 spike.

260 dentify patients more likely to die from the SARS-CoV-2 infection, regardless of age.

261 lights proteolytic degeneracy wired into the SARS-CoV-2 lifecycle.

262 le organ failure, suggesting a spread of the SARS-CoV-2 in blood.

263 iliated cells as potential reservoirs of the SARS-CoV-2 receptor.

264 leavage contributes to the activation of the SARS-CoV-2 S glycoprotein, we evaluated the ability of p

265 al dispersal and increasing frequency of the SARS-CoV-2 spike protein variant D614G are suggestive of

266 nt of guidance to reduce transmission of the SARS-CoV-2 virus, responsible for the COVID-19 pandemic.

267 An essential protein of the SARS-CoV-2 virus, the envelope protein E, forms a homope

268 ate-dependent epidemic model to simulate the SARS-CoV-2 pandemic by probing different scenarios based

269 We reveal that the SARS-CoV-2 virus becomes more infectious.

270 Strikingly, unlike the SARS-CoV-2-like coronaviruses (CoVs) identified in bats

271 Antibodies to SARS-CoV-2 predicted the odds of developing acute respir

272 AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavi

273 n contrast to mice, are highly permissive to SARS-CoV-2 and develop bronchopneumonia and strong infla

274 veolar type-II-like cells) are permissive to SARS-CoV-2 infection, and showed robust induction of che

275 do not know regarding our immune response to SARS-CoV-2, and provide a number of scenarios for which

276 found sex differences in immune responses to SARS-CoV-2 and the predictors of disease progression.

277 Antibody responses to SARS-CoV-2 are unimodally distributed over a broad range

278 protective or pathogenic immune responses to SARS-CoV-2 infection remains unknown.

279 of the Spanish population is seronegative to SARS-CoV-2 infection, even in hotspot areas.

280 Recent studies have shown that, similarly to SARS-CoV, SARS-CoV-2 utilises the Spike glycoprotein on

281 y to the S protein and neutralized wild-type SARS-CoV-2 virus in a synergistic manner.

282 e of the entry receptor is key to understand SARS-CoV-2 tropism, transmission and pathogenesis.

283 e insights for development of more universal SARS-like coronavirus vaccines and therapies.

284 cluding in infections with the related virus SARS-CoV.

285 n the context of IFN-I pretreatment, whereas SARS-CoV is not.

286 goal of this study was to determine whether SARS-CoV-2 RNA could be detected from NP samples via a d

287 -driven BCR clusters closely associated with SARS-CoV-2 antibodies.

288 me-wide CRISPR screens in Vero-E6 cells with SARS-CoV-2, Middle East respiratory syndrome CoV (MERS-C

289 ing infection of AT2 and basal cultures with SARS-CoV-2 and identifying club cells as a target popula

290 S-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbre

291 red information on 94 patients with IEI with SARS-CoV-2 infection.

292 of individuals that have been infected with SARS-CoV-2 even if the infection was asymptomatic.

293 y and high-risk APOL1 genotype infected with SARS-CoV-2 have emerged during the COVID-19 pandemic.

294 Although the diagnosis of infection with SARS-CoV-2 is microbiological, imaging techniques play a

295 Infection with SARS-CoV-2 occurred in 42 participants recommended masks

296 nanswered question is whether infection with SARS-CoV-2 results in protective immunity against reexpo

297 VID-19, the disease caused by infection with SARS-CoV-2, requires urgent development of therapeutic i

298 We challenge organoids with SARS-CoV-2 spike pseudovirus and live virus to demonstra

299 mell was more prevalent in participants with SARS-CoV-2 antibodies, compared with those without antib

300 nt it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-sp

301 ed symptoms in participants with and without SARS-CoV-2 antibodies.